Loading…
Reported covered position: N/A
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Access to Life-Saving Medicine Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
S.1082, FDA Revitalization Act HR 2900, The FDA Amendments Act of 2007 S. 623 and HR 1038, Access to Life Saving Medicines Act S. 1695, Biologics Price Completion and Innovation Act of 2007
Access to Life-Saving Medicine Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
S. 1145 and HR 1908, Patent Reform Act of 2006 S. 316, The Preserve Access to Affordable Generics Act
S. 3, relating to fair prescription drug prices for Medicare Beneficiaries HR 4, Medicare Prescription Drug Price Negotiation Act of 2007 Issues relating to Medicaid rebate
Source: Senate LDA
Issues relating to Medicaid drug pricing fraud HR 477 and S 999, Stop Stroke Act Issues relating to prevention of diversion and abuse of controlled substances Issues relating to pharmaceutical compounding Issues relating to the Montreal Protocol S. 1082, FDA Revitalization Act HR 2900, The FDA Amendments Act of 2007 S. 623 and HR 1038, Access to Life Saving Medicines Act S. 1695, Biologics Price Completion and Innovation Act of 2007
Access to Life-Saving Medicine Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
S.1082, FDA Revitalization Act HR 2900, The FDA Amendments Act of 2007 S. 623 and HR 1038, Access to Life Saving Medicines Act S. 1695, Biologics Price Completion and Innovation Act of 2007 Issues relating to Medicaid drug pricing fraud HR 477 and S 999, Stop Stroke Act Issues relating to prevention of diversion and abuse of controlled substances Issues relating to pharmaceutical compounding Issues relating to Montreal Protocol
Food and Drug Administration Amendments Act of 2007
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
S.1082, FDA Revitalization Act HR 2900, The FDA Amendments Act of 2007 S. 623 and HR 1038, Access to Life Saving Medicines Act S. 1695, Biologics Price Completion and Innovation Act of 2007
Food and Drug Administration Amendments Act of 2007
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues relating to Medicaid drug pricing fraud HR 477 and S 999, Stop Stroke Act Issues relating to prevention of diversion and abuse of controlled substances Issues relating to pharmaceutical compounding Issues relating to the Montreal Protocol S. 1082, FDA Revitalization Act HR 2900, The FDA Amendments Act of 2007 S. 623 and HR 1038, Access to Life Saving Medicines Act S. 1695, Biologics Price Completion and Innovation Act of 2007
Food and Drug Administration Amendments Act of 2007
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
S.1082, FDA Revitalization Act HR 2900, The FDA Amendments Act of 2007 S. 623 and HR 1038, Access to Life Saving Medicines Act S. 1695, Biologics Price Completion and Innovation Act of 2007 Issues relating to Medicaid drug pricing fraud HR 477 and S 999, Stop Stroke Act Issues relating to prevention of diversion and abuse of controlled substances Issues relating to pharmaceutical compounding Issues relating to Montreal Protocol
Medicare Prescription Drug Price Negotiation Act of 2007
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
S. 3, relating to fair prescription drug prices for Medicare Beneficiaries HR 4, Medicare Prescription Drug Price Negotiation Act of 2007 Issues relating to Medicaid rebate
Medicare Prescription Drug Price Negotiation Act of 2007
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
S. 3, relating to fair prescription drug prices for Medicare beneficiaries HR. 4, Medicare Prescription Drug Price Negotiation Act of 2007 Issues relating to Medicaid rebate
Medicare Prescription Drug Price Negotiation Act of 2007
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
S. 3, relating to fair prescription drug prices for Medicare beneficiaries HR 4, Medicare Prescription Drug Price Negotiation Act of 2007 Issues relating to Medicaid rebate
Stroke Treatment and Ongoing Prevention Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues relating to Medicaid drug pricing fraud HR 477 and S 999, Stop Stroke Act Issues relating to prevention of diversion and abuse of controlled substances Issues relating to pharmaceutical compounding Issues relating to the Montreal Protocol S. 1082, FDA Revitalization Act HR 2900, The FDA Amendments Act of 2007 S. 623 and HR 1038, Access to Life Saving Medicines Act S. 1695, Biologics Price Completion and Innovation Act of 2007
Stroke Treatment and Ongoing Prevention Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
S.1082, FDA Revitalization Act HR 2900, The FDA Amendments Act of 2007 S. 623 and HR 1038, Access to Life Saving Medicines Act S. 1695, Biologics Price Completion and Innovation Act of 2007 Issues relating to Medicaid drug pricing fraud HR 477 and S 999, Stop Stroke Act Issues relating to prevention of diversion and abuse of controlled substances Issues relating to pharmaceutical compounding Issues relating to Montreal Protocol
Foreign Investment and National Security Act of 2007
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
S.1610, Foreign Investment and National Security Act of 2007 HR 556, National Security Foreign Investment Reform and Strengthened Transparency Act of 2007 Issues relating to Tariff
Foreign Investment and National Security Act of 2007
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
S. 1610, Foreign Investment and National Security Act of 2007 HR 556, National Security Foreign Investment Reform and Strengthened Transparency Act of 2007 Issues relating to Tariff
Foreign Investment and National Security Act of 2007
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
S.1610, Foreign Investment and National Security Act of 2007 HR 556, National Security Foreign Investment Reform and Strengthened Transparency Act of 2007 Issues relating to Tariff
Biologics Price Competition and Innovation Act of 2007
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
S.1082, FDA Revitalization Act HR 2900, The FDA Amendments Act of 2007 S. 623 and HR 1038, Access to Life Saving Medicines Act S. 1695, Biologics Price Completion and Innovation Act of 2007 Issues relating to Medicaid drug pricing fraud HR 477 and S 999, Stop Stroke Act Issues relating to prevention of diversion and abuse of controlled substances Issues relating to pharmaceutical compounding Issues relating to Montreal Protocol
Biologics Price Competition and Innovation Act of 2007
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues relating to Medicaid drug pricing fraud HR 477 and S 999, Stop Stroke Act Issues relating to prevention of diversion and abuse of controlled substances Issues relating to pharmaceutical compounding Issues relating to the Montreal Protocol S. 1082, FDA Revitalization Act HR 2900, The FDA Amendments Act of 2007 S. 623 and HR 1038, Access to Life Saving Medicines Act S. 1695, Biologics Price Completion and Innovation Act of 2007
Biologics Price Competition and Innovation Act of 2007
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
S.1082, FDA Revitalization Act HR 2900, The FDA Amendments Act of 2007 S. 623 and HR 1038, Access to Life Saving Medicines Act S. 1695, Biologics Price Completion and Innovation Act of 2007
Medicare Prescription Drug Price Negotiation Act of 2007
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
S. 3, relating to fair prescription drug prices for Medicare Beneficiaries HR 4, Medicare Prescription Drug Price Negotiation Act of 2007 Issues relating to Medicaid rebate
Medicare Prescription Drug Price Negotiation Act of 2007
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
S. 3, relating to fair prescription drug prices for Medicare beneficiaries HR 4, Medicare Prescription Drug Price Negotiation Act of 2007 Issues relating to Medicaid rebate
Medicare Prescription Drug Price Negotiation Act of 2007
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
S. 3, relating to fair prescription drug prices for Medicare beneficiaries HR. 4, Medicare Prescription Drug Price Negotiation Act of 2007 Issues relating to Medicaid rebate
Preserve Access to Affordable Generics Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
S. 1145 & HR 1908, Patent Reform Act of 2006 S. 316, The Preserve Access to Affordable Generics Act
Preserve Access to Affordable Generics Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
S. 1145 and HR 1908, Patent Reform Act of 2006 S. 316, The Preserve Access to Affordable Generics Act
Preserve Access to Affordable Generics Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
S.1145 and HR 1908, Patent Reform Act of 2006 S. 316, The Preserve Access to Affordable Generics Act
Access to Life-Saving Medicine Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
S.1082, FDA Revitalization Act HR 2900, The FDA Amendments Act of 2007 S. 623 and HR 1038, Access to Life Saving Medicines Act S. 1695, Biologics Price Completion and Innovation Act of 2007 Issues relating to Medicaid drug pricing fraud HR 477 and S 999, Stop Stroke Act Issues relating to prevention of diversion and abuse of controlled substances Issues relating to pharmaceutical compounding Issues relating to Montreal Protocol
Access to Life-Saving Medicine Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues relating to Medicaid drug pricing fraud HR 477 and S 999, Stop Stroke Act Issues relating to prevention of diversion and abuse of controlled substances Issues relating to pharmaceutical compounding Issues relating to the Montreal Protocol S. 1082, FDA Revitalization Act HR 2900, The FDA Amendments Act of 2007 S. 623 and HR 1038, Access to Life Saving Medicines Act S. 1695, Biologics Price Completion and Innovation Act of 2007
Access to Life-Saving Medicine Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
S.1082, FDA Revitalization Act HR 2900, The FDA Amendments Act of 2007 S. 623 and HR 1038, Access to Life Saving Medicines Act S. 1695, Biologics Price Completion and Innovation Act of 2007
Stroke Treatment and Ongoing Prevention Act of 2008
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues relating to Medicaid drug pricing fraud HR 477 and S 999, Stop Stroke Act Issues relating to prevention of diversion and abuse of controlled substances Issues relating to pharmaceutical compounding Issues relating to the Montreal Protocol S. 1082, FDA Revitalization Act HR 2900, The FDA Amendments Act of 2007 S. 623 and HR 1038, Access to Life Saving Medicines Act S. 1695, Biologics Price Completion and Innovation Act of 2007
Stroke Treatment and Ongoing Prevention Act of 2008
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
S.1082, FDA Revitalization Act HR 2900, The FDA Amendments Act of 2007 S. 623 and HR 1038, Access to Life Saving Medicines Act S. 1695, Biologics Price Completion and Innovation Act of 2007 Issues relating to Medicaid drug pricing fraud HR 477 and S 999, Stop Stroke Act Issues relating to prevention of diversion and abuse of controlled substances Issues relating to pharmaceutical compounding Issues relating to Montreal Protocol
Local Law Enforcement Enhancement Act of 2005
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
S.1145 and HR 1908, Patent Reform Act of 2006 S. 316, The Preserve Access to Affordable Generics Act
Local Law Enforcement Enhancement Act of 2005
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
S. 1145 & HR 1908, Patent Reform Act of 2006 S. 316, The Preserve Access to Affordable Generics Act
Local Law Enforcement Enhancement Act of 2005
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
S. 1145 and HR 1908, Patent Reform Act of 2006 S. 316, The Preserve Access to Affordable Generics Act
Pharmaceutical Market Access Act of 2005
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
HR. 5009, Ryan White CARE Act Amendments of 2006 Issues relating to pharmaceutical compounding Issues relating to Medicare Part D Issues relating to CFC Supply and essentiality S. 3807, Enhancing Drug Safety and Innovation Act of 2006 S. 4016 and HR. 6257, Access to Life Saving Medicine Act S. 3695, relating to the prohibition of authorized generic drugs HR. 328, Pharmaceutical Market Access Act of 2005 S. 109, Pharmaceutical Market Access Act of 2005 HR. 6143, The Ryan White HIV/AIDS Treatment Modernization Act S. 2339, Ryan White CARE Act Amendments of 2006
Animal Enterprise Terrorism Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
HR. 4239, Animal Enterprise Terrorism Act S. 1926, Animal Terrorism Act
Ryan White CARE Act Amendments of 2006
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
HR. 5009, Ryan White CARE Act Amendments of 2006 Issues relating to pharmaceutical compounding Issues relating to Medicare Part D Issues relating to CFC Supply and essentiality S. 3807, Enhancing Drug Safety and Innovation Act of 2006 S. 4016 and HR. 6257, Access to Life Saving Medicine Act S. 3695, relating to the prohibition of authorized generic drugs HR. 328, Pharmaceutical Market Access Act of 2005 S. 109, Pharmaceutical Market Access Act of 2005 HR. 6143, The Ryan White HIV/AIDS Treatment Modernization Act S. 2339, Ryan White CARE Act Amendments of 2006
A bill to suspend temporarily the duty on aerosol valves designed to deliver a metered dose (50 microliters) of a pressurized liquid pharmaceutical.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
HR. 6111 Tax Relief and Health Care Act of 2006 HR. 4944, Miscellaneous Trade and Technical Corrections Act of 2006 S. 2505, Duty Suspension on aerosol valves S. 3549, Foreign Investment and National Security Act of 2006 HR. 5337, National Secruity Foregin Investment Reform and Strengthened Transparency Act of 2006
Foreign Investment and National Security Act of 2006
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
HR. 6111 Tax Relief and Health Care Act of 2006 HR. 4944, Miscellaneous Trade and Technical Corrections Act of 2006 S. 2505, Duty Suspension on aerosol valves S. 3549, Foreign Investment and National Security Act of 2006 HR. 5337, National Secruity Foregin Investment Reform and Strengthened Transparency Act of 2006
A bill to amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
HR. 5009, Ryan White CARE Act Amendments of 2006 Issues relating to pharmaceutical compounding Issues relating to Medicare Part D Issues relating to CFC Supply and essentiality S. 3807, Enhancing Drug Safety and Innovation Act of 2006 S. 4016 and HR. 6257, Access to Life Saving Medicine Act S. 3695, relating to the prohibition of authorized generic drugs HR. 328, Pharmaceutical Market Access Act of 2005 S. 109, Pharmaceutical Market Access Act of 2005 HR. 6143, The Ryan White HIV/AIDS Treatment Modernization Act S. 2339, Ryan White CARE Act Amendments of 2006
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2007
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
HR. 3010, Making Appropriations for the Departments of Labor, Health and Human Services and Education for FY 2007 S. 3708, Making Appropriations for the Departments of Labor, Health and Human Services and Education for FY 2007 HR. 544, Making Appropriation for the Department of Homeland Security for FY 2007 S. CON. RES. 83, Congressional Budget for Government for FY 2007 HR. 2744 Making Appropriations for Agriculture, Rural Development, Food and Drug Administration and Related Agencies for FY 2007
Enhancing Drug Safety and Innovation Act of 2006
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
HR. 5009, Ryan White CARE Act Amendments of 2006 Issues relating to pharmaceutical compounding Issues relating to Medicare Part D Issues relating to CFC Supply and essentiality S. 3807, Enhancing Drug Safety and Innovation Act of 2006 S. 4016 and HR. 6257, Access to Life Saving Medicine Act S. 3695, relating to the prohibition of authorized generic drugs HR. 328, Pharmaceutical Market Access Act of 2005 S. 109, Pharmaceutical Market Access Act of 2005 HR. 6143, The Ryan White HIV/AIDS Treatment Modernization Act S. 2339, Ryan White CARE Act Amendments of 2006
Patent Reform Act of 2006
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
S.3818, Patent Reform Act of 2006 HR 2795, relating to the procurement, enforcement and validy of patents
Access to Life-Saving Medicine Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
HR. 5009, Ryan White CARE Act Amendments of 2006 Issues relating to pharmaceutical compounding Issues relating to Medicare Part D Issues relating to CFC Supply and essentiality S. 3807, Enhancing Drug Safety and Innovation Act of 2006 S. 4016 and HR. 6257, Access to Life Saving Medicine Act S. 3695, relating to the prohibition of authorized generic drugs HR. 328, Pharmaceutical Market Access Act of 2005 S. 109, Pharmaceutical Market Access Act of 2005 HR. 6143, The Ryan White HIV/AIDS Treatment Modernization Act S. 2339, Ryan White CARE Act Amendments of 2006
Protocol Amending the Convention Between the United States and Germany for the Avoidance of Double Taxation and the Prevention of Fiscal Evasion with Respect to Taxes on Income and Capital and to Certain Other Taxes (Treaty Doc. 109-20)
S.1610, Foreign Investment and National Security Act of 2007 HR 556, National Security Foreign Investment Reform and Strengthened Transparency Act of 2007 Issues relating to Tariff
S.1082, FDA Revitalization Act HR 2900, The FDA Amendments Act of 2007 S. 623 and HR 1038, Access to Life Saving Medicines Act S. 1695, Biologics Price Completion and Innovation Act of 2007 Issues relating to Medicaid drug pricing fraud HR 477 and S 999, Stop Stroke Act Issues relating to prevention of diversion and abuse of controlled substances Issues relating to pharmaceutical compounding Issues relating to Montreal Protocol
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), Treasury, Dept of, UNDETERMINED
S.1610, Foreign Investment and National Security Act of 2007 HR 556, National Security Foreign Investment Reform and Strengthened Transparency Act of 2007 Issues relating to Tariff
S.1082, FDA Revitalization Act HR 2900, The FDA Amendments Act of 2007 S. 623 and HR 1038, Access to Life Saving Medicines Act S. 1695, Biologics Price Completion and Innovation Act of 2007
Protocol Amending the Convention Between the United States and Germany for the Avoidance of Double Taxation and the Prevention of Fiscal Evasion with Respect to Taxes on Income and Capital and to Certain Other Taxes (Treaty Doc. 109-20)
S.1145 and HR 1908, Patent Reform Act of 2006 S. 316, The Preserve Access to Affordable Generics Act
S. 3, relating to fair prescription drug prices for Medicare beneficiaries HR 4, Medicare Prescription Drug Price Negotiation Act of 2007 Issues relating to Medicaid rebate
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), Treasury, Dept of
Issues relating to Medicaid drug pricing fraud HR 477 and S 999, Stop Stroke Act Issues relating to prevention of diversion and abuse of controlled substances Issues relating to pharmaceutical compounding Issues relating to the Montreal Protocol S. 1082, FDA Revitalization Act HR 2900, The FDA Amendments Act of 2007 S. 623 and HR 1038, Access to Life Saving Medicines Act S. 1695, Biologics Price Completion and Innovation Act of 2007
S. 1610, Foreign Investment and National Security Act of 2007 HR 556, National Security Foreign Investment Reform and Strengthened Transparency Act of 2007 Issues relating to Tariff
S. 3, relating to fair prescription drug prices for Medicare beneficiaries HR. 4, Medicare Prescription Drug Price Negotiation Act of 2007 Issues relating to Medicaid rebate
Protocol Amending the Convention Between the United States and Germany for the Avoidance of Double Taxation and the Prevention of Fiscal Evasion with Respect to Taxes on Income and Capital and to Certain Other Taxes (Treaty Doc. 109-20)
S. 1145 & HR 1908, Patent Reform Act of 2006 S. 316, The Preserve Access to Affordable Generics Act
Filing targets: Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), Treasury, Dept of
HR. 5009, Ryan White CARE Act Amendments of 2006 Issues relating to pharmaceutical compounding Issues relating to Medicare Part D Issues relating to CFC Supply and essentiality S. 3807, Enhancing Drug Safety and Innovation Act of 2006 S. 4016 and HR. 6257, Access to Life Saving Medicine Act S. 3695, relating to the prohibition of authorized generic drugs HR. 328, Pharmaceutical Market Access Act of 2005 S. 109, Pharmaceutical Market Access Act of 2005 HR. 6143, The Ryan White HIV/AIDS Treatment Modernization Act S. 2339, Ryan White CARE Act Amendments of 2006
HR. 3010, Making Appropriations for the Departments of Labor, Health and Human Services and Education for FY 2007 S. 3708, Making Appropriations for the Departments of Labor, Health and Human Services and Education for FY 2007 HR. 544, Making Appropriation for the Department of Homeland Security for FY 2007 S. CON. RES. 83, Congressional Budget for Government for FY 2007 HR. 2744 Making Appropriations for Agriculture, Rural Development, Food and Drug Administration and Related Agencies for FY 2007
Issues pertaining to H-1B Visa
S.3818, Patent Reform Act of 2006 HR 2795, relating to the procurement, enforcement and validy of patents
HR. 4239, Animal Enterprise Terrorism Act S. 1926, Animal Terrorism Act
HR. 6111 Tax Relief and Health Care Act of 2006 HR. 4944, Miscellaneous Trade and Technical Corrections Act of 2006 S. 2505, Duty Suspension on aerosol valves S. 3549, Foreign Investment and National Security Act of 2006 HR. 5337, National Secruity Foregin Investment Reform and Strengthened Transparency Act of 2006
Filing targets: Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS)
Filing targets: Commerce, Dept of (DOC), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS)
Filing targets: Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE